PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

THE OBJECTIVE IS AN EVALUATION OF EFFICACY, SAFETY AND TOLERABILITY OF THE PERMIXON IN PATIENTS WITH BENIGN PROSTATIC HYPERTROPHY
Article published in Urologia Polska 2000/53/2.

authors

Piotr Kryst 1, Ewa KoĽmińska, Romuald Zdrojowy, Zenona Jabłońska 2, Jerzy Lorenz, Andrzej Borkowski
1 Klinika Urologii AM w Warszawie
Kierownik Kliniki: prof. dr hab. med. A. Borkowski
2 Klinika Urologii AM we Wrocławiu
Kierownik Kliniki: prof. dr hab. med. J. Lorenz

keywords

prostate, benign prostatic hyperplasia, Permixon

summary

Objectives. Objective was an evaluation of efficacy safety and tolerability of
the Permixon? in patients with benign prostatic hypertrophy.
Material and method. Results of the clinical trial with 60 patients treated by
Permixon 320 mg daily during 12 weeks are presented. Statistic analysis of I-
PSS, QoL, Qmax/ Qave, Rvol, Voiding time and Voided Volume was done.
Results. The results show significant statistic improvement of all treatment
parameters. We think the use of Permixon? is effective and safe in men with
Symptomatic benign prostatic hypertrophy.
Conclusions. 1. The treatment of patients in the initial phase of BPH is save
and effective. 2. The therapeutic effect is considered as diminishing of dysuria,
quality of life as well as urodynamic parameters improvement. 3. The therapeutic
effect is observed after 4 weeks of treatment onset. 4. The risk of side effect is low.

references

  1. [1] Barry, M.)., Cockett, A. T., Holtgrewe, H. L, Mc Donell, J. D., Sihelnik,
  2. S. A., Winfield, H. N.: Relationship of symptoms of prostatism to commonly
  3. used physiological and anatomical measures of the severity of benign prostatic hy-
  4. perplasia. J. Urol. 1993,150, 351-358.
  5. [2] Barry, M. J., Mulley, A. G., Fowler, F. J., Wennberg, J. W.: Watchful wait-
  6. ing vs immediate transurethral resection for Symptomatic prostatism. The impor-
  7. tance of patients preferences. JAMA 1988, 259, 3010-3017.
  8. [3] Borkowski, A., Borówka, A.: Choroby gruczołu krokowego. Wydawnictwo
  9. Lekarskie PZWL, Warszawa 1997, 86-106.
  10. [4] Came, M.: Alpha-adrenergic blockersfor the treatment of benign prostatic hyper-
  11. plasia. Urol. Clin. N. Amer. 1990,17, 641-649.
  12. [5] Carraro, J. C, Raynaud, J. R, Koch, G., Chisholm, G., Di Silveno, F.,
  13. Teillac, R, Da Silva, R, Cau±uil, J., Chopin, D., Hamdy, R, Hanu¶, M.,
  14. Haun, D., Kalinteris, A., Marencak, J., Pener, A., Perrin, R: Comparison
  15. of phytotherapy (Permixonm) with finasteride in the treatment of benign prostate
  16. hyperplasia: a randomized international study of 1098 patients. Prostate 1996, 29,
  17. 231-240.
  18. [6] Champault, G., Patel, J. C, Bonnard, A. M.: A double blind trial of an
  19. extract of the plant Serenoa repens in BPH. Brit. J. Clin. Pharmacol 1984, 18,
  20. 461-462.
  21. [7] Christmas, T. ]., Kirby, R. S.: Alpha-adrenoreceptor blockers in the treatment
  22. of benign prostatic hyperplasia. World J. Urol. 1991, 9, 36-40.
  23. [8] Department of Veterans Affairs Cooperative Study of Transurethral Resec-
  24. tion for Benign Prostatic Hyperplasia: A Comparison of' ±uality of life with pa-
  25. tient reported symptoms and objectwefindings in men with benign prostatic hyper-
  26. plasia. }. Urol. 1993,150,1696-1700.
  27. [9] Di Salle, E., Briatico, G., Giudici, D., Oriati, G., Panzeri, A.: Endocrine
  28. properties of the testosterone 5a-reductase inhibitor turostende (FCE 26073). J.
  29. Steroid. Biochem. Molec. Biol. 1994, 48, 241-248.
  30. [10] Di Silverio, R, D'Eramo, G., Lubrano, C, Flammia, G. R, Sciarra, A.,
  31. Palma, E., Caponera, M., Sciarra, F.: Evidence that Serenoa repens eztract
  32. displays an antiestrogenic activity in prostatic tissue of benign prostatic hyperpla-
  33. sia patients. Eur. Urol. 1992, 21, 309-314.
  34. [11] Duker, E. M., Kopanski, L., Schweikert, H. U.: Inhibition of 5a-reductase
  35. actwity by extractsfrom sabal serrulata. Planta Medica 1989, suppl. 5, abstr. L2-2.
  36. [12] Garraway, W. M., Collins, G. N., Lee, R. J.: High prevalence of benign pro-
  37. static hyperplasia in the community. Lancet 1991, 338, 469-471.